The Prognosis For Palvella Therapeutics
Palvella Therapeutics has seen a significant increase in its stock price following promising Phase 3 trial results for its treatment of microcystic lymphatic malformations. The company's QTORIN rapamycin showed strong efficacy and safety in the trials. This surge in stock value reflects investor confidence in the company's future prospects.
- ▪Palvella Therapeutics stock has surged over sevenfold post-IPO.
- ▪The increase is driven by strong Phase 3 results for QTORIN rapamycin.
- ▪QTORIN rapamycin demonstrated significant efficacy and safety in treating microcystic lymphatic malformations.
Opening excerpt (first ~120 words) tap to expand
{"@context":"https://schema.org","@type":"BreadcrumbList","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https://seekingalpha.com/"},{"@type":"ListItem","position":2,"name":"Healthcare ","item":"https://seekingalpha.com/stock-ideas/healthcare"}]}{"@context":"https://schema.org","@type":"NewsArticle","mainEntityOfPage":{"@type":"WebPage","@id":"https://seekingalpha.com/article/4911560-the-prognosis-for-palvella-therapeutics"},"author":{"@type":"Person","name":"Bret Jensen","url":"https://seekingalpha.com/author/bret-jensen"},"publisher":{"@context":"http://schema.org","@type":"Organization","address":{"@type":"PostalAddress","streetAddress":"244 5th Ave","addressLocality":"New…
Excerpt limited to ~120 words for fair-use compliance. The full article is at Seeking Alpha.
Discussion
0 commentsMore from Seeking Alpha
